

**Form 42**

*Securities Act*

**REPORT OF TAKE-OVER BID, ISSUER BID OR APPLICATION UNDER  
CLAUSE 104(2) (c) OF THE ACT**

(Subsection 203.1 (1) of the Regulation)

1. Name and address of the offeree issuer: CliniChem Development Inc., 275 Armand-Frappier Boulevard, Laval, Quebec, H7V 4A7
2. Name and address of the offeror: BioChem Pharma Inc., 275 Armand-Frappier Boulevard, Laval, Quebec, H7V 4A7
3. The designation of the class of securities that are subject to the bid and the CUSIP number is: Class A common shares, CUSIP number 186906.
4. The date of the bid is July 28, 2000.
5. The maximum number of securities sought by the offeror for each class of securities subject to the bid is: 396,274 Class A common shares, which includes no outstanding options or other rights to acquire or receive Class A common shares currently exercisable.
6. The value, expressed in Canadian dollars, of the consideration offered per security for each class of securities subject to the bid is: \$14.23 (based on the noon buying rate on July 28, 2000 in New York, certified by the New York Federal Reserve Bank for customs purposes of US\$1.00 to CDN\$1.4776) per Class A common share.
7. The number of securities of each class subject to the bid, excluding the offeror's securities, that are held by security holders whose last address as shown on the books of the offeree issuer is in Ontario, is: 396,274 Class A common shares.
8. The fee payable in respect of the bid, as calculated under subsection 32(1) of Schedule 1 is \$900.00.
9. The information given in this report is true and complete.

August 17, 2000

**BIOCHEM PHARMA INC.**  
(Name of the Offeror)

By: (signed) François Legault  
François Legault  
Executive Vice President, Development and  
Investments